A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioWest Therapeutics Inc

Criteria

Inclusion Criteria:

• The patient must be 18 to 65 years of age, inclusive.

• Primary diagnosis of chronic HCV infection.

Exclusion Criteria:

• Patients who did not respond or relapsed following therapy with interferon.